Inoviq Ltd · ASX:IIQ
Inoviq — MST Access Diagnostics Forum 2022
24 slides from Inoviq's conference presentation, Dec 6, 2022
Slide 1: MST Access Diagnostics Forum notice
MST Access Diagnostics Forum notice Melbourne, Australia, 5 December 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advises that CEO Dr Leearne Hinch will deliver the attached presentation to investors and shareholders at the MST Access Diagnostics Forum on 6 December 2022. The Diagnostics F
Slide 2: Investor Presentation - MST Access Diagnostics Forum
Investor Presentation 6 December 2022 MST Access Diagnostics Forum ASX: IIQ
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 4: INOVIQ highlights
INOVIQ highlights Next-generation exosome capture tools and precision diagnostics Patented technology platforms for biomarker isolation and detection Products in-market for exosome research & bladder cancer $ Multi-product cancer diagnostics pipeline targeting large global markets Compelling early d
Slide 5: INOVIQ snapshot
INOVIQ snapshot Financial information (ASX:IIQ) Share price performance Ordinary shares2 92,018,702 Listed options2 5,909,965 Share price2 A$0.630 Market capitalisation2 A$58.0m Cash at bank1 A$13.5m Ave monthly cash burn3 A$607k Major shareholders (as at 2 December 2022) Board and Management Mercha
Slide 6: Pipeline | Multiple shots on goal
Pipeline | Multiple shots on goal ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC2 (OCRF-7) Ovarian Cancer Multiomic Screenin
Slide 7: Indications for Use | Tests for different cancers and uses in the diagnostic pathway
Indications for Use | Tests for different cancers and uses in the diagnostic pathway BEFORE DIAGNOSIS AFTER DIAGNOSIS SCREENING DIAGNOSIS TREATMENT MONITORING SELECTION Test use Earlier detection in Aiding and confirming Staging and triage-to- Monitoring asymptomatic people diagnosis treatment treat
Slide 8: Ovarian Cancer | Overview
Ovarian Cancer | Overview • #8 most common cancer & #1 gynaecological cancer deaths in women worldwide 5-year Survival by Stage at Diagnosis2 • UNMET NEED for earlier and more accurate tests for OC detection and monitoring Normal Stage 1 Stage 2 Stage 3 Stage 4 Healthy ovaries Confined to Spread wit
Slide 9: OC Screening | Exosomal ovarian cancer screening test
OC Screening | Exosomal ovarian cancer screening test Collaboration with UQ to develop blood-based exosomal screening test for ovarian cancer1 AA OCRF-7 OCRF-7 BB CA-125 • UQ’s OCRF-7 validated in a retrospective case- 1.0 1.0 1.0 1.0 control study achieving over 90% accuracy for detection of stage
Slide 10: OC Screening | Exosomal OC test planned studies
OC Screening | Exosomal OC test planned studies Next-steps 1. Ovarian Cancer 97 Study: To establish that EXO-NET is fit-for-purpose for the downstream analysis of plasma extracellular vesicle associated microRNA and protein and for use in MRFF Ovarian Cancer Screening Study (UQ) 2. OC 250 Study: Ana
Slide 11: Breast Cancer | Overview
Breast Cancer | Overview • #1 most common cancer & #1 cancer deaths in women worldwide 5-year Survival by Stage at Diagnosis2 • UNMET NEED for earlier and more accurate tests for BC detection and monitoring prevalence 7.8m $4.2b1 incidence 2.3m Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 BREAST CANCER d
Slide 12: BC Monitoring | SubB2M-based Breast Cancer monitoring test
BC Monitoring | SubB2M-based Breast Cancer monitoring test • SubB2M-based immunoassay development, optimisation and BC 95 Study: Breast Cancer Clinical Study validation underway at ResearchDx1,2 • Commenced breast cancer clinical study (BC95) to evaluated performance of SubB2M-CA15.3 by cancer stage
Slide 13: BC Monitoring | SubB2M Breast Cancer monitoring study
BC Monitoring | SubB2M Breast Cancer monitoring study Intended use: A blood test to aid in monitoring breast cancer recurrence Prospectively Collected Retrospectively Analysed Longitudinal Breast Cancer Study Study Design Prospective Longitudinal Clinical Cohort Study Objective CA15.3 is still a wid
Slide 14: BC Monitoring | SubB2M Breast Cancer monitoring study (cont.)
BC Monitoring | SubB2M Breast Cancer monitoring study (cont.) Intended use: A blood test to aid in monitoring breast cancer recurrence 2022 2023 Post-treatment histologically/ pathologically confirmed diagnosis of breast cancer (n=200) Serum samples collected at 3,6,12,24,48 months Neu5Gc-CA15.3 & C
Slide 15: Cancer Risk Assessment | SubB2M-based SPR test
Cancer Risk Assessment | SubB2M-based SPR test • POC data in case-control studies showed the SubB2M-based SPR test detected: o Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) 1,2 o Breast Cancer at 95% sensitivity and 100% specificity across all stages (n = 118) 1,
Slide 16: Diagnostics | Commercialisation strategy
Diagnostics | Commercialisation strategy Stepped approach to commercialisation: Laboratory Developed Test In Vitro Diagnostic (LDT) (IVD) • Market entry: Initially US, then expand to EU, AU and others CLIA FDA 510k clearance / PMA approval • Regulatory: Initially LDT, then IVD route Development & va
Slide 17: Market potential | Screening and monitoring
Market potential | Screening and monitoring Eligible screening Screening market Eligible monitoring Monitoring market Statistics1 population2 size3 population4 size5 11.5 1.7 4.0 0.6 Ovarian cancer incidence 28.0 9.1 188.3 52,638 60.4 $1.9b 4 Ovarian 119m USD $18b 367k 25.1 USD $55m GLOBAL Dx 54.7 M
Slide 18: Exosomes | Diagnostic and therapeutic potential
Exosomes | Diagnostic and therapeutic potential Exosomes are small extracellular vesicles (sEVs; 30-150nm) released from most cells, including cancer cells, into body fluids (plasma, saliva, urine, CSF) EXOSOMES contain biomolecules (DNA, RNAs, proteins) and deliver these “messages” between cells Ex
Slide 19: EXO-NET | Exosome isolation tools
EXO-NET I Exosome isolation tools • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids • Meets and unmet need for rapid, efficient and scalable isolation of exosomes • Suitable for biomarker discovery, research & development phases of future
Slide 20: EXO-NET | Speed, purity and yield advantages
EXO-NET | Speed, purity and yield advantages FAST Easy and convenient workflow with EV capture in 15 minutes Optimal solution for very low volume and rare samples from plasma, urine, SAMPLE VERSATILITY saliva HIGH YIELD High yield and capture of EVs from various biofluids Reduced co-isolation of con
Slide 21: EXO-NET | Efficient Isolation of plasma EV derived RNAs
EXO-NET I Efficient Isolation of plasma EV derived RNAs EXONET outperforms or is equivalent to 4 EXONET comparison to 4 commercial kits 45.00 commercial EV isolation kits for recovery of EV micro RNA (miRNA) and messenger (mRNA) as indicated by lower CT values.1,2 40.00 Mean CT Value 35.00 30.00 “Th
Slide 22: Key achievements of 2022 and catalysts for 2023
Key achievements of 2022 and catalysts for 2023 PoC results for Balance sheet Brands unified ResearchDx UQ collaboration to EXO-NET US sales SubB2M-CA125 strengthened: under new engaged for dev develop world-first force engaged to Several key test for OC $18.4m raised name: INOVIQ / validation of ex
Slide 23: Contacts
Contacts INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 22
Slide 24: Board and Management
Board and Management DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and international Healthcare industry dire